Videos
Clinical Conversations by Experts
View all

Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives
- Imaging the Immune System: CD8 T-Cell Tracking for Cancer and Autoimmune Disease - Anna Wu
- Covalent Radioligands Advance Precision in Tumor Targeting - Andreas Goutopoulos
- Lead-212 Radiopharmaceuticals Offer Promise in Targeted Cancer Treatment - Volker Wagner View all Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives videos

Managing Small Renal Masses in Renal Cell Carcinoma Videos
- The Value and Limitations of Biopsies for Small Renal Masses - Phillip Pierorazio
- Advancing Imaging Techniques for Small Renal Mass Diagnosis and Clinical Decision-Making - Sam Chang
- Functional Renal Imaging and Advances in Kidney Cancer Detection - Shankar Siva View all Managing Small Renal Masses in Renal Cell Carcinoma Videos videos
Featured Videos

PIVOT-006: Phase III Trial of Creto vs Surveillance in Intermediate-Risk Bladder Cancer - Mark Tyson

PEACE 3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad

Durvalumab Plus Guadecitabine in Metastatic Kidney Cancer: Phase 1/2 Trial Results - Yousef Zakharia

Access and Utilization of Healthcare by Adults with Spina Bifida - Lindsay Hampson & Alejandro Lopez

Probing the Promising Future of Anti-HER2 Therapies for Micropapillary Bladder Cancer - Jeffrey Ross

Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi

A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore

Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell

The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris

Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
Genomic Classifier in Prostate Cancer: High-Risk
High-Risk Non-Muscle Invasive Bladder Cancer
Advanced Bladder Cancer
Integrating (177Lu)–PSMA-617: A Practical Approach for Urology Clinics
Beyond Androgen Blockade - Exploring New Pathways for Treating mCRPC and mHSPC
APCCC 2024
Latest Videos
EMBARK
Recent Conference Coverage
Conference Highlights Written by Physician-Scientist

The 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
- ASCO GU 2025: Prospective Real World Data Evaluation of Clinical Outcomes in mHSPC Patients Treated as Part of Triplet Therapy with Darolutamide: UK Multicenter RECOmMEnD Study
- ASCO GU 2025: Prostate Cancer Risk Groups by PSMA-PET PROMISE: Results from an International Multi-Center Registry Study
- ASCO GU 2025: PSMA-Based Therapy in Advanced Disease: Touching on Combination Sequencing

2024 Society of Urologic Oncology (SUO) Annual Meeting
- SUO 2024: Biomarkers and Clinical Predictors in RCC
- SUO 2024: Update on Neoadjuvant Therapy Trials in RCC
- SUO 2024: Joseph A Smith, Jr. Mentorship Award Lecture
Recent Physician-Scientist Review Articles
State of the Evidence Review Articles

Advanced Bladder Cancer
- The Quickly Evolving Treatment Landscape of Metastatic Urothelial Carcinoma: A New Standard of Care in First-Line Systemic Therapy
Written by Zachary Klaassen, MD, MSc Associate Professor of Urology Urologic Oncologist Medical College of Georgia, Georgia Cancer Center Augusta, GA and Rashid Sayyid, MD, MSc Urologic Oncology Fellow University of Toronto Toronto, Ontario, Canada
- The Treatment Landscape of Metastatic Urothelial Carcinoma: Second-Line Systemic Therapy
Written by Zachary Klaassen, MD, MSc Associate Professor of Urology Urologic Oncologist Medical College of Georgia, Georgia Cancer Center Augusta, GA and Rashid Sayyid, MD, MSc Urologic Oncology Fellow University of Toronto Toronto, Ontario, Canada

PSMA-Targeted Therapy
- Beyond a VISION to Making a SPLASH: Advances in PSMA-Based Theranostics in Prostate Cancer
Written by Zachary Klaassen, MD, MSc, Medical College of Georgia, Augusta, Georgia
Transformative Evidence
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
ANKTIVA
ASCO GU 2025: ResQ132A: Phase 2 Trial of Intravesical Gemcitabine Plus N-803 Versus Intravesical N-803 and BCG for Intermediate-Risk NMIBC
Presented by Sandeep Reddy, MD
The 2025 GU ASCO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Sandeep Reddy discussing ResQ132A, a phase 2 trial of intravesical gemcitabine + N-803 versus intravesical N-803 and BCG for intermediate-risk non-muscle invasive papillary bladder cancer (NMIBC). Read More
ARANOTE
ASCO GU 2025: Darolutamide + ADT in Patients with mHSPC by Disease Volume: Subgroup Analysis of the Phase 3 ARANOTE Trial
Presented by Fred Saad, MD, FRCS
The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Fred Saad discussing a subgroup analysis of the phase 3 ARANOTE trial assessing darolutamide + ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume. Darolutamide + ADT significantly reduced the risk of radiological progression or death by 46% (HR 0.54, 95% CI 0.41–0.71; p < 0.0001) versus placebo plus ADT in patients with mHSPC in the ARANOTE trial. Read More
Trials in Progress
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
CORE-008 Trial
ASCO GU 2025: CORE-008: A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study To Evaluate Intravesical Cretostimogene Grenadenorepvec in Participants With High-Risk NMIBC
Presented by Trinity Bivalacqua, MD
The 2025 GU ASCO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Trinity Bivalacqua discussing CORE-008, a phase 2, multi-arm, multi-cohort, open-label study to evaluate intravesical cretostimogene grenadenorepvec in participants with high-risk non-muscle invasive bladder cancer. Read More
CLARIFY Trial
ASCO GU 2025: CLARIFY: PET Using 64Cu-SAR-bisPSMA in Patients with High-Risk Prostate Cancer Prior to Radical Prostatectomy—A Phase 3 Diagnostic Performance Study
Presented by Michael A. Gorin, MD
The 2025 GU ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Michael Gorin discussing CLARIFY, a phase 3 diagnostic performance study assessing PET using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy. Prostate cancer is the second most prevalent cancer in men globally. In men with newly diagnosed, high-risk disease, prostate cancer most often spreads to the pelvic lymph nodes before becoming widely metastatic. Read More